Published Studies

	BIOVAXID™		Chronic Sinusitis

BIOVAXID Immunotherapy for Non-Hodgkin's Lymphoma

Overview Article

DarM, Kwak, et al. Vaccination Strategies for Lymphomas

Neelapu, et al. Review Article

Early Publications on Anti-Id Vaccines

Below are various clinical trial and summary papers detailing the progress of the BIOVAXID vaccine:

Kwak et al, 1992 publication reporting on the use of Stanford anti-idiotype vaccine:

Kwak L, Campbell M, et al. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N Engl J Med 1992; 327(17): 1209-15

In 1996, Kwak, et al. published on the use of simulatenous, free granulocyte/monocyte-colony stimulating factor (GM-CSF):

Kwak LW, Young H, et al. Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response. Proc. Natl. Acad. Sci USA 1996; 93:10972-10977

Stanford Open-Label Studies

Weng, et al. Clinical Outcome of Lymphoma Patients After Idiotype Vaccination Is Correlated With Humoral Immune Response and Immunoglobulin G Fc Receptor Genotype. J. Clin. Oncol. December 1, 2004; 22(22) 4717-4724

Clinical Trials to Date

Followup and long-term results of the Stanford anti-idiotype vaccine (Hsu, et al)

Hsu FJ, Caspar CB, Czerwinski D, et al. Tumor-specific idiotype vaccines in the treatment
of patients with B-cell lymphoma: Long-term results of a clinical trial. Blood 89:3129-3135, 1997

Phase II Clinical Trial at the NCI (20 patients)

Bendandi M, Gocke CD, Kobrin CB, et al: Complete molecular remissions induced by
patient-specific vaccination plus granulocytemonocyte colony-stimulating factor against lymphoma.
Nat Med 5:1171-1177, 1999

Phase II Followup (August 2005)

Santos C, Stern L, et al. BiovaxID Vaccine Therapy of Follicular Lymphoma in First Remission: Long-Term Follow-Up of a Phase II Trial and Status of a Controlled, Randomized Phase III Trial. [Submitted to ASH Conference Abstracts Dec. 2005]

Phase III Interim Report (June 2005)

Neelapu S, Gause B, et al. Phase III Randomized Trial of Patient-Specific Vaccination for Previously Untreated Patients with Follicular Lymphoma in First Complete Remission: Protocol Summary and Interim Report. Clin Lymphoma. June 2005 (Vol. 6, No. 01)

Mantle Cell Lymphoma: BiovaxID vaccination after Rituxan

Neelapu S, Kwak L, et al. Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma. Nat. Med. 2005 [published online Aug 21, 2005]

Usage in Relapse Follicular Lymphoma (new)

Inoges S, Rodriguez-Calvillo M, et al. Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma.
J Natl Cancer Inst. 2006 Sep 20;98(18):1292-301.

Longo, DL. Idiotype vaccination in follicular lymphoma: knocking on the doorway to cure. J Natl Cancer Inst. 2006 Sep 20;98(18):1263-5

Ongoing Clinical Trials at the NCI for BIOVAXID

1. Ongoing Phase II Trial for Mantle Cell Lymphoma
   
2. Ongoing Phase II Trial for Multiple Myeloma

Literature on Bcl-2/Molecular Remissions (New)

Download article archive (4mb)

Intraclonal variability of VH genes in Lymphoma

Yanez, et al. Intraclonal Variability of VH Genes in Follicular Lymphoma Patients Who Have Received
Anti-Idiotypic Immunotherapy. 2006; J Immunother. 29(1):61-66.